(Q38631443)

4 September 2017

title

Checkpoint inhibitors in Hodgkin's lymphoma (English)

1 reference

4 September 2017

author name string

Barbara Jezeršek Novaković

series ordinal

1

1 reference

4 September 2017

publication date

11 November 2015

1 reference

European Journal of Haematology

4 September 2017

published in

1 reference

4 September 2017

volume

96

1 reference

4 September 2017

issue

4

1 reference

4 September 2017

page(s)

335-343

1 reference

XVII. Radiotherapy in early stage Hodgkin lymphoma

4 September 2017

cites work

1 reference

Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)

21 January 2018

1 reference

Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial

21 January 2018

1 reference

Long-term results of conventional-dose salvage chemotherapy in patients with refractory and relapsed Hodgkin's disease (Croatian experience).

21 January 2018

1 reference

Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy

21 January 2018

1 reference

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

21 January 2018

1 reference

Managing relapsed and refractory Hodgkin lymphoma

21 January 2018

1 reference

Treatment for primary refractory Hodgkin's disease: a comparison of high-dose chemotherapy followed by ASCT with conventional therapy.

21 January 2018

1 reference

Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome.

21 January 2018

1 reference

Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma.

21 January 2018

1 reference

Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma

21 January 2018

1 reference

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma

21 January 2018

1 reference

Vinorelbine: an active drug for the management of patients with heavily pretreated Hodgkin's disease

21 January 2018

1 reference

Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma

21 January 2018

1 reference

Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma

21 January 2018

1 reference

Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma.

21 January 2018

1 reference

Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin's lymphoma

21 January 2018

1 reference

New drugs and targeted treatments in Hodgkin's lymphoma

21 January 2018

1 reference

Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all!

21 January 2018

1 reference

Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study

21 January 2018

1 reference

The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape.

21 January 2018

1 reference

CD28 interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes

21 January 2018

1 reference

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

21 January 2018

1 reference

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

PD-1 and its ligands in tolerance and immunity

21 January 2018

1 reference

Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family

21 January 2018

1 reference

The PD-1 pathway in tolerance and autoimmunity

21 January 2018

1 reference

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms

21 January 2018

1 reference

Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor

21 January 2018

1 reference

Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+.

21 January 2018

1 reference

Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer

21 January 2018

1 reference

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients

21 January 2018

1 reference

Putting the brakes on BTLA in T cell-mediated cancer immunotherapy

21 January 2018

1 reference

The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation

21 January 2018

1 reference

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

21 January 2018

1 reference

Immune checkpoint blockade in hematologic malignancies

21 January 2018

1 reference

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

21 January 2018

1 reference

Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells

21 January 2018

1 reference

CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.

21 January 2018

1 reference

Novel immunotherapies for hematologic malignancies

21 January 2018

1 reference

The new therapeutical scenario of Hodgkin lymphoma

21 January 2018

1 reference

Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade

21 January 2018

1 reference

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

21 January 2018

1 reference

MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers

21 January 2018

1 reference

Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy

21 January 2018

1 reference

PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies

21 January 2018

1 reference

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

21 January 2018

1 reference

Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality

21 January 2018

1 reference

Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion

21 January 2018

1 reference

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

21 January 2018

1 reference

Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma

21 January 2018

1 reference

CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation

21 January 2018

1 reference

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

21 January 2018

1 reference

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

21 January 2018

1 reference

Blocking tumor escape in hematologic malignancies: the anti-PD-1 strategy

21 January 2018

1 reference

Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies

21 January 2018

1 reference

Combining immunotherapy and targeted therapies in cancer treatment

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/EJH.12697

1 reference

4 September 2017

1 reference